We leverage leading-edge technologies to create highly targeted small molecule treatments for the pharmaceutical industry.
Our approach is entirely patient-centric and focuses on diseases with significant unmet needs that cause maximal negative impact to public health.
Our focus is on identifying biological signaling pathways with well validated and understood biology that drive diseases with high unmet need, where validated druggable targets within these pathways have proven hard to drug.
We utilize advanced computational chemistry alongside other technologies to more effectively leverage high-resolution protein structural data for drugging targets outside their natural ligand binding site and modulating the protein’s activity.
